Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
暂无分享,去创建一个
Matthias Ernst | M. Ernst | A. Chand | D. Gough | Ashwini Chand | Jennifer Huynh | Daniel Gough | J. Huynh
[1] M. Augsten. Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment , 2014, Front. Oncol..
[2] J. Bromberg,et al. Touched and Moved by STAT3 , 2006, Science's STKE.
[3] H. Zhang,et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.
[4] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[5] J. Turkson,et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction , 2010, Aging.
[6] Guangxu Jin,et al. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative and HER2-enriched breast cancers , 2017, Oncogene.
[7] C. Datz,et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.
[8] E. Yeh,et al. SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer , 2016, Oncogene.
[9] A. Butte,et al. Widespread parainflammation in human cancer , 2016, Genome Biology.
[10] Kuen-Feng Chen,et al. Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma , 2014, Hepatology.
[11] J. Darnell,et al. Essential Role of STAT3 in Postnatal Survival and Growth Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation , 2004, Molecular and Cellular Biology.
[12] Can Alkan,et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gamma delta-T or NK cells , 2022 .
[13] Fiona M. Watt,et al. Epithelial stem cells, wound healing and cancer , 2012, Nature Reviews Cancer.
[14] O. Sieber,et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.
[15] N. Reich,et al. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis , 2018, Genes & development.
[16] S. Snapper,et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages , 2017, Science.
[17] S. Rose-John,et al. The role of IL-6 in host defence against infections: immunobiology and clinical implications , 2017, Nature Reviews Rheumatology.
[18] I. Noth,et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production , 2018, Science Translational Medicine.
[19] M. Dietrich,et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1 , 2009, Nature Cell Biology.
[20] L. Zitvogel,et al. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. , 2015, Cancer research.
[21] W. Alexander,et al. General Nature of the STAT3-Activated Anti-Inflammatory Response1 , 2006, The Journal of Immunology.
[22] B. Becher,et al. Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation. , 2016, Cell reports.
[23] J. Turkson,et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. , 2010, Cancer research.
[24] R. Balaban,et al. Stoichiometry of STAT3 and Mitochondrial Proteins , 2010, The Journal of Biological Chemistry.
[25] J. Pollard,et al. Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.
[26] Hua Yu,et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. , 2014, The Journal of clinical investigation.
[27] M. Goldsmith,et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. , 2006, Blood.
[28] J. Darnell,et al. Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.
[29] G. Stark,et al. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2 , 2015, Proceedings of the National Academy of Sciences.
[30] M. Neurath,et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing , 2009, The Journal of experimental medicine.
[31] Xinbing Sui,et al. The role of STAT3 in autophagy , 2015, Autophagy.
[32] S. Heymans,et al. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy , 2013, EMBO molecular medicine.
[33] Fei Xing,et al. Cancer associated fibroblasts (CAFs) in tumor microenvironment. , 2010, Frontiers in bioscience.
[34] V. Poli,et al. STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca2+ fluxes and apoptotic responses , 2018, Cell Death & Differentiation.
[35] V. Sanz-Moreno,et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts , 2015, Nature Communications.
[36] Alex J. Walsh,et al. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. , 2015, Gastroenterology.
[37] D. Scheuner,et al. Regulation of starvation- and virus-induced autophagy by the eIF2α kinase signaling pathway , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[39] Q. Cai,et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. , 2016, Blood.
[40] S. Mustjoki,et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.
[41] R. Jove,et al. Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.
[42] Jing Ma,et al. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements , 2006 .
[43] V. Poli,et al. STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance , 2015, Front. Oncol..
[44] Chuang Zhou,et al. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer , 2018, Scientific Reports.
[45] Yu Qin,et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. , 2016, Cancer letters.
[46] V. Fried,et al. Cellular Physiology of STAT3: Where’s the Cytoplasmic Monomer?* , 1999, The Journal of Biological Chemistry.
[47] Hua Yu,et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.
[48] P. Jung,et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.
[49] V. Poli,et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. , 2006, The Journal of cell biology.
[50] Y. E. Chin,et al. Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.
[51] B. Ammori,et al. Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients , 2014, Journal of immunology research.
[52] P. Rosenstiel,et al. ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling , 2018, The Journal of experimental medicine.
[53] N. Gray,et al. Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition , 2018, Proceedings of the National Academy of Sciences.
[54] S. Rose-John,et al. Interleukin-6: designing specific therapeutics for a complex cytokine , 2018, Nature Reviews Drug Discovery.
[55] J. Joyce,et al. STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation. , 2016, Cell reports.
[56] Wenjun Cheng,et al. Activated Signal Transducer and Activator of Transcription (STAT) 3 , 2004, Cancer Research.
[57] Ash A. Alizadeh,et al. Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.
[58] K. Rajewsky,et al. STAT3 Activation in Th17 and Th22 Cells Controls IL-22–Mediated Epithelial Host Defense during Infectious Colitis , 2014, The Journal of Immunology.
[59] G. Moseley,et al. The Rabies Virus Interferon Antagonist P Protein Interacts with Activated STAT3 and Inhibits Gp130 Receptor Signaling , 2013, Journal of Virology.
[60] J. Fagin,et al. STAT3 negatively regulates thyroid tumorigenesis , 2012, Proceedings of the National Academy of Sciences.
[61] M. Talpaz,et al. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. , 2018, Blood.
[62] Daniel Nathans,et al. Specific Ablation of Stat3β Distorts the Pattern of Stat3-Responsive Gene Expression and Impairs Recovery from Endotoxic Shock , 2002, Cell.
[63] S. Akira,et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.
[64] Jennifer R. Grandis,et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.
[65] D. Tweardy,et al. Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation , 2009, PloS one.
[66] Sami Al-Hajjar,et al. B cell–intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans , 2010, The Journal of experimental medicine.
[67] P Jay,et al. Specific inhibition of Stat3 signal transduction by PIAS3. , 1997, Science.
[68] K. Kiguchi,et al. Stat3 binds to mitochondrial DNA and regulates mitochondrial gene expression in keratinocytes , 2014, The Journal of investigative dermatology.
[69] R. Kalluri. The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.
[70] S. Fuller,et al. IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1 , 2015, The Journal of Immunology.
[71] E. Vellenga,et al. Ser727‐dependent transcriptional activation by association of p300 with STAT3 upon IL‐6 stimulation , 2001, FEBS letters.
[72] T. Putoczki,et al. ReviewStat 3 : linking inflammation to epithelial cancer-more than a " gut " feeling ? , 2015 .
[73] Chin Wee Tan,et al. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration , 2014, Science Signaling.
[74] Sreenath V. Sharma,et al. A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation , 2011, Oncotarget.
[75] P. Sehgal,et al. Membrane-associated STAT3 and PY-STAT3 in the Cytoplasm* , 2006, Journal of Biological Chemistry.
[76] K. Heeg,et al. PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3 , 2011, European journal of immunology.
[77] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[78] A. Horiguchi,et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma , 2010, British Journal of Cancer.
[79] Long-Bang Chen,et al. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway , 2016, Scientific Reports.
[80] R. Medzhitov. Origin and physiological roles of inflammation , 2008, Nature.
[81] C. Shiau,et al. Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells , 2018, Cell Death Discovery.
[82] P. Russell,et al. IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. , 2016, Cancer research.
[83] Hua Yu,et al. Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.
[84] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[85] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[86] T. Reinheckel,et al. Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis , 2018, Cell.
[87] J. O’Shea,et al. Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs , 2018, Journal of leukocyte biology.
[88] K. Müller,et al. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells. , 2018, Journal of natural products.
[89] C. Fielding,et al. IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT31 , 2008, The Journal of Immunology.
[90] Jian-Ting Zhang,et al. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? , 2018, Pharmacology & therapeutics.
[91] J. Darnell,et al. Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.
[92] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[93] Y. Ben-Neriah,et al. Inflammatory networks underlying colorectal cancer , 2016, Nature Immunology.
[94] S. Tangye,et al. Insights into the Role of STAT3 in Human Lymphocyte Differentiation as Revealed by the Hyper-IgE Syndrome1 , 2009, The Journal of Immunology.
[95] J. Darnell,et al. Interacting Regions in Stat3 and c-Jun That Participate in Cooperative Transcriptional Activation , 1999, Molecular and Cellular Biology.
[96] P. Fawcett,et al. Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.
[97] Massimo Gadina,et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.
[98] T. Putoczki,et al. Molecular Pathways: IL11 as a Tumor-Promoting Cytokine—Translational Implications for Cancers , 2014, Clinical Cancer Research.
[99] C. Watson,et al. Stat3 controls cell death during mammary gland involution by regulating uptake of milk fat globules and lysosomal membrane permeabilization , 2014, Nature Cell Biology.
[100] D. Davar,et al. Toll-Like Receptor 9 Agonists in Cancer , 2020, OncoTargets and therapy.
[101] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[102] Luke Barron,et al. Macrophages: Master Regulators of Inflammation and Fibrosis , 2010, Seminars in liver disease.
[103] E. Yang,et al. The Role of STAT-3 in Cetuximab-induced Radiosensitization in Head-and-Neck Cancer Cells , 2012 .
[104] L. Nelles,et al. Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases , 2013, The Journal of Immunology.
[105] Quin F. Wills,et al. Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease , 2018, Cell.
[106] J. Nemunaitis,et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.
[107] C. Burns,et al. Targeting JAK kinase in solid tumors: emerging opportunities and challenges , 2016, Oncogene.
[108] Erik Sahai,et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. , 2011, Cancer cell.
[109] S. Dewilde,et al. The STAT3 isoforms α and β have unique and specific functions , 2004, Nature Immunology.
[110] J. Turkson,et al. Stat3 controls lysosomal-mediated cell death in vivo , 2011, Nature Cell Biology.
[111] D. Levy,et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.
[112] P. Aigner,et al. STAT3 isoforms: Alternative fates in cancer? , 2019, Cytokine.
[113] M. Scheulen,et al. Toll-like receptor 9 agonists as cancer therapeutics , 2011, Expert opinion on investigational drugs.
[114] L. Kenner,et al. The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. , 2009, Frontiers in bioscience.
[115] R. Jove,et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.
[116] Hua Yu,et al. CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. , 2017, Cancer research.
[117] Can Alkan,et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells , 2015, Nature Communications.
[118] P. Dent,et al. Mitochondrial Localized Stat3 Promotes Breast Cancer Growth via Phosphorylation of Serine 727* , 2013, The Journal of Biological Chemistry.
[119] M. Kortylewski,et al. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients , 2015, Clinical Cancer Research.
[120] Ash A. Alizadeh,et al. Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .
[121] M. J. Ruiz,et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. , 2011, Blood.
[122] Jing Zhang,et al. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma. , 2013, Neuro-oncology.
[123] M. Delorenzi,et al. RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation , 2017, Cell Death and Differentiation.
[124] Christine A Iacobuzio-Donahue,et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression , 2016, Nature Medicine.
[125] L. Zitvogel,et al. STAT3 inhibition for cancer therapy: Cell-autonomous effects only? , 2016, Oncoimmunology.
[126] Yuli Lin,et al. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. , 2016, Cancer research.
[127] K. Hess,et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo , 2007, Oncogene.
[128] Jeou-Yuan Chen,et al. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44 , 2009, The Journal of cell biology.
[129] R. Xiang,et al. Tumor‐Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox‐2 Signaling Pathway , 2013, Stem cells.
[130] D. Nam,et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.
[131] G. Stark,et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes , 2010, Proceedings of the National Academy of Sciences.
[132] L. Qin,et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer , 2018, Oncogene.
[133] E. Casanova,et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.
[134] Hua Yu,et al. A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors. , 2011, Cancer research.
[135] F. Uckun,et al. Role of the Leukemia-associated Transcription Factor STAT3 in Platelet Physiology , 2002, Leukemia & lymphoma.
[136] R. Boidot,et al. Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. , 2017, Cell reports.
[137] S. Akira,et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.
[138] S. Akira,et al. Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.
[139] W. Frankel,et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. , 2013, Cancer research.
[140] Jongdae Lee,et al. Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition in Apcmin/+ Mice via Regulation of Snail-1 (SNAI) Protein Stability* , 2012, The Journal of Biological Chemistry.
[141] A. Neunkirchner,et al. STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[142] A. D. Panopoulos,et al. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. , 2010, Blood.
[143] H. Katabuchi,et al. Involvement of M2‐polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation , 2010, Cancer science.
[144] D. Levy,et al. Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.
[145] P. Schumacker,et al. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.
[146] Yinghui Zhu,et al. ANGPTL1 Interacts with Integrin α1β1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling. , 2017, Cancer research.
[147] J. Scheller,et al. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.
[148] J. Grandis,et al. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer , 2015, PloS one.
[149] K. Polyak,et al. Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity , 2014, Nature.
[150] M. Tremblay,et al. Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation , 2010, PLoS ONE.
[151] G. Laurent,et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis , 2012, EMBO molecular medicine.
[152] Wei Liu,et al. Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma , 2018, Cell Death & Disease.
[153] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[154] A. Taketomi,et al. IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway , 2015, Scientific Reports.
[155] David E Levy,et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.
[156] E. Elinav,et al. IL-22 Deficiency Alters Colonic Microbiota To Be Transmissible and Colitogenic , 2013, The Journal of Immunology.
[157] Hua Yu,et al. Activated Signal Transducers and Activators of Transcription 3 Signaling Induces CD46 Expression and Protects Human Cancer Cells from Complement-Dependent Cytotoxicity , 2007, Molecular Cancer Research.
[158] C. Drake,et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.
[159] H. A. Rogoff,et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness , 2015, Proceedings of the National Academy of Sciences.
[160] P. Heinrich,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.
[161] Ozge Canli,et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.
[162] W. Bamlet,et al. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. , 2014, Cancer discovery.
[163] Riitta Lahesmaa,et al. Genome-wide Analysis of STAT3-Mediated Transcription during Early Human Th17 Cell Differentiation. , 2017, Cell reports.
[164] E. O'Duibhir,et al. The STAT3–IL-10–IL-6 Pathway Is a Novel Regulator of Macrophage Efferocytosis and Phenotypic Conversion in Sterile Liver Injury , 2018, The Journal of Immunology.
[165] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[166] L. Galluzzi,et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. , 2012, Molecular cell.
[167] S. Watowich,et al. STAT3 signaling in immunity. , 2016, Cytokine & growth factor reviews.
[168] J. Kere,et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease , 2014, Nature Genetics.
[169] R. Flavell,et al. STAT3 is required for Flt3L-dependent dendritic cell differentiation. , 2003, Immunity.
[170] H. Tamaki,et al. STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[171] Kevin M. McBride,et al. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[172] D. Levy,et al. STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. , 2014, Blood.
[173] V. Poli,et al. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. , 2006, Blood.
[174] L. Hennighausen,et al. Janus Kinase 1 Is Essential for Inflammatory Cytokine Signaling and Mammary Gland Remodeling , 2016, Molecular and Cellular Biology.
[175] R. Ahmed,et al. STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells , 2014, The Journal of Immunology.
[176] B. Groner,et al. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.
[177] Hua Yu,et al. CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. , 2016, Immunity.
[178] D. Tu,et al. The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC). , 2014 .
[179] N. Nicola,et al. Inhibition of IL-6 family cytokines by SOCS3. , 2014, Seminars in immunology.
[180] G. Stark,et al. Roles of unphosphorylated STATs in signaling , 2008, Cell Research.
[181] Johannes Zuber,et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis , 2015, Nature Communications.
[182] A. Heimberger,et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. , 2007, Cancer research.
[183] H. Ochs,et al. Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation. , 2012, The Journal of allergy and clinical immunology.
[184] S. Akira,et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[185] J. Licht,et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.
[186] K. Hwang,et al. Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages toward regulatory subsets , 2013 .
[187] R. Banerjee,et al. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug , 2017, Molecular and Cellular Biochemistry.
[188] Hua Yu,et al. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis , 2015, Cancer Immunology Research.
[189] D. Levy,et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.
[190] R. Dickins,et al. Generation of an inducible mouse model to reversibly silence Stat3 , 2017, Genesis.
[191] J. Ritz,et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.
[192] Keshava Rajagopal,et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.
[193] G. Bepler,et al. Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[194] V. Poli,et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. , 2014, Blood.
[195] Tao Yang,et al. IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer , 2016, Tumor Biology.
[196] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[197] M. Neurath,et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.
[198] Hua Yu,et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. , 2015, The Journal of clinical investigation.
[199] B. Jenkins,et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice , 2002, Nature Medicine.
[200] J. Zucman‐Rossi,et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.
[201] S. Mustjoki,et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. , 2012, Blood.
[202] Traci M. Blonquist,et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. , 2016, Blood.
[203] J. Darnell,et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.
[204] A. Giraud,et al. Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells , 2016, Scientific Reports.